BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Cancer / Immunology

EU Approves HUTCHMED's FRUZAQLA® for Previously Treated Metastatic Colorectal Cancer

— Approval for previously treated metastatic colorectal cancer based on results from positive, global, Phase III FRESCO-2 Trial — — FRUZ...

June 24, 2024 | News

Juniper Biologics Expands Distribution Rights for Caris Life Sciences' Advanced Cancer Profiling Services to Middle East and Africa

Singapore-headquartered Juniper Biologics Pte Ltd (Juniper), a leading healthcare and pharmaceuticals company focused on commercialising novel therapies, h...

June 24, 2024 | News

ReviR Therapeutics and Asieris Pharmaceuticals Achieve Milestone in Cancer Treatment Collaboration

ReviR Therapeutics, a biotechnology company specializing in the development of small molecule RNA splicing modulators for neurogenetic diseases and oncolog...

June 18, 2024 | News

FDA Clears Zymeworks' ZW171 for Mesothelin-Expressing Cancers

“We are excited to reach this R&D milestone with ZW171, reflecting our commitment to advancing innovative therapies for cancer treatment,...

June 18, 2024 | News

Thermo Fisher Scientific, NUH, and Mirxes Collaborate to Enhance Access to Advanced Genomic Cancer Testing in Singapore

To increase patient access to affordable, advanced genomic testing for cancer in Singapore, Thermo Fisher Scientific Inc., the world leader in serving scie...

June 14, 2024 | News

EnGeneIC and Singapore Institute of Advanced Medicine Partner to Transform Cancer Treatment in Asia

EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has announce...

June 07, 2024 | News

Telix Pharmaceuticals Submits NDA for Innovative Prostate Cancer Imaging Kit to FDA

Telix Pharmaceuticals announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA...

May 27, 2024 | News

Aptamer Group Signs £465,000 Agreement for Development of Cervical Cancer Blood Test

Agreement for up to £465,000 signed for Optimer development Optimer binders will be developed for use in a cervical cance...

May 22, 2024 | News

Ractigen Therapeutics' saRNA Drug RAG-01 Receives Fast Track Designation from FDA

Ractigen Therapeutics, a pioneering developer of small activating RNA (saRNA) therapeutics, proudly announces that its flagship program, RAG-01, has been g...

May 22, 2024 | News

NUS Scientists Discover Novel Method to Activate Muscle Cells’ Natural Defences Against Cancer Using Magnetic Pulses

A team of researchers led by Associate Professor Alfredo Franco-Obregón from the NUS Institute for Health Innovation & Technology (iHealthtech) ...

May 22, 2024 | News

BeiGene and Glenmark Forge Strategic Partnership to Distribute Innovative Cancer Treatments in India

BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced a new partnership with Glenmark Specialty S.A. (Glen...

May 21, 2024 | News

Telix Pharmaceuticals' CUPID Study Demonstrates Promising Results for Next-Generation Prostate Cancer Therapy

CUPID is a Phase I safety and dosimetry study of TLX592, Telix's investigational antibody-based targeted alpha therapy for prostate cancer. Establishes ...

May 21, 2024 | News

AstraZeneca Announces $1.5 Billion Manufacturing Facility in Singapore for Cutting-Edge Cancer Treatments

AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global s...

May 20, 2024 | News

Amplexd Therapeutics Secures $2 Million in Strategic Funding to Advance Non-Invasive Treatments for HPV-Induced Cervical Precancers

Amplexd Therapeutics, Inc. (“Amplexd” or the “Company”), a clinical stage patient-scientist-led biotech company specializing in acc...

May 20, 2024 | News

Stay Connected